You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Product overview

Relvar Ellipta is an ICS/LABA combination for the treatment of asthma and COPD [1] [2]. Relvar is the only ICS/LABA which is one inhalation, once daily, due to its unique component combination which delivers 24 hours of continuous efficacy.

Request a placebo

Theravance logo

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Relvar and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies